What We're Reading: Page 43
Industry reads hand-picked by our editors
Aug 20, 2024
-
The New York Times
He Regulated Medical Devices. She Represented Their Makers.
-
Bloomberg
Eli Lilly Tests Zepbound for Psoriasis, Immunology
-
FirstWord Pharma
Lundbeck ups guidance on higher expectations for Rexulti, Vyepti
-
ApexOnco
Just how independent is Genentech?
Aug 19, 2024
Aug 16, 2024
-
Bloomberg
Weight-Loss Drug Market to Lack Competition for Years, Zealand CEO Says
-
Endpoints News
Genentech dissolves cancer immunology group, and research executive Ira Mellman will leave company
-
CNBC
Bayer shares soar 11% after key U.S. legal win against Roundup cancer claims
-
STAT
The business of CRISPR’d medicine: Not great
Aug 15, 2024
-
The Financial Times
How Roche passed on a potential $14bn-a-year weight-loss pill
-
KFF Health News
Opioid Settlements Promise Mississippi a Windfall. What Happens Next?
-
BioCentury
No sleep for the biotech bear: Restructurings abound in August
Previous
